Shire PLC (LON:SHP)‘s stock had its “buy” rating reaffirmed by analysts at Shore Capital in a report issued on Thursday.
SHP has been the subject of several other reports. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 6,300 ($82.23) price objective on shares of Shire PLC in a research note on Tuesday, August 16th. Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,600 ($73.10) price target on shares of Shire PLC in a research report on Monday, June 13th. BNP Paribas reiterated an “outperform” rating and set a GBX 5,700 ($74.40) price target on shares of Shire PLC in a research report on Wednesday, June 15th. Jefferies Group lifted their price target on Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Shire PLC in a research report on Friday, July 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Shire PLC has a consensus rating of “Buy” and an average target price of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5196.00 on Thursday. The stock’s 50 day moving average price is GBX 4,985.70 and its 200 day moving average price is GBX 4,560.67. The stock’s market capitalization is GBX 35.48 billion. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.
The business also recently disclosed a dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 8th were paid a dividend of GBX 3.51 ($0.05) per share. This represents a yield of 0.07%. The ex-dividend date was Thursday, September 8th.
In related news, insider Dominic Blakemore acquired 133 shares of the stock in a transaction on Friday, September 30th. The shares were bought at an average price of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.